Document Detail

Optimal Management of Recurrent Prostate Cancer in Older Patients.
MedLine Citation:
PMID:  23135826     Owner:  NLM     Status:  Publisher    
With a large, aging population in the USA and continued prolongation of life expectancy, treatment of cancer in the elderly will continue to be of importance. The most common cancer in men is prostate cancer, which is most often diagnosed in those over the age of 65 years. Initial therapies for prostate cancer are local treatments in those with localized disease and for whom definitive therapy is appropriate. Optimal treatment of an older patient with recurrent prostate cancer now involves more of a decision process than treatment has in the past, with the recent approval of several new medical agents for advanced prostate cancer. Through this article we will focus on treatment options for recurrent prostate cancer, keeping in mind the unique characteristics of the elderly population. A majority of the discussion will focus on many of the newly approved agents used to treat castration-resistant prostate cancer, and exciting agents currently under investigation. Improved androgen blockade has improved overall survival in patients with metastatic disease but carries many of the same adverse effects as previous agents. Newer approaches with immunotherapy, radiopharmaceuticals, or second-generation androgen receptor blockers introduce a different adverse-effect profile for older patients. As data matures, these too may improve survival for patients with metastatic disease. Throughout all stages of disease, one must keep in mind the unique needs of an older patient population.
Elizabeth R Kessler; Thomas W Flaig
Related Documents :
9616446 - A comparison of artificial saliva and pilocarpine in the management of xerostomia in pa...
23540746 - Managing the risks of cardiac therapy in cancer patients.
21740356 - The molecular basis of herpesviruses as oncolytic agents.
25083226 - Risks and benefits with bevacizumab: evidence and clinical implications.
25329306 - Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human l...
19900856 - Cooperative group research efforts in thoracic malignancies 2009: a review from the 10t...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Drugs & aging     Volume:  -     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine, Mail Stop 8117, 12801 E. 17th Avenue, Room L18-8117, Aurora, CO, 80045-0511, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoe...
Next Document:  The toxic effect of chitosan/metal-impregnated textile to synanthropic mites.